Uppsala, Sweden, May 20, 2026. Dicot Pharma AB announces that the company has successfully completed manufacturing of the drug candidate LIB-01 as a tablet for the planned phase 2b study, which is intended to start in the second half of 2026.
Dicot Pharma is conducting preparations ahead of the planned phase 2b clinical study of its drug candidate LIB-01, developed as a new treatment concept for erectile dysfunction.
Today, the company announced that the manufacturing of LIB-01 tablets for the planned phase 2b study has been completed according to plan. Tablets containing both the active substance and placebo have been manufactured. The tablets will next be packaged in blisters and labeled for use in the study.
The plan is to initiate the clinical study during the second half of 2026.
“Tablet manufacturing is one of several important steps in the preparations, which we are now completing according to plan, for the upcoming phase 2b study of LIB-01, a drug candidate that has the potential to give millions of men with erectile dysfunction and their partners the opportunity for a better sex life,” says Elin Trampe, CEO of Dicot Pharma.